News blog

GSK absorbs controversial ‘longevity’ company

Pharma giant GlaxoSmithKline will close Sirtris Pharmaceuticals, a firm intent on developing compounds that stave off age-related disease — and one of GSK’s most contentious acquisitions. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE